SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Muñoz-Rodríguez, F-J
Right arrow Articles by Ordinas, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muñoz-Rodríguez, F-J
Right arrow Articles by Ordinas, A
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Lupus
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus

F-J Muñoz-Rodríguez

Systemic Autoimmune Diseases Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

J-C Reverter

Department of Haemotherapy and Haemostasis, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

J Font

Systemic Autoimmune Diseases Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

D Tàssies

Department of Haemotherapy and Haemostasis, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

G Espinosa

R Cervera

Systemic Autoimmune Diseases Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

F Carmona

J Balasch

Department of Gynecology and Obstetrics, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

M Ingelmo

Systemic Autoimmune Diseases Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

A Ordinas

Department of Haemotherapy and Haemostasis, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

Antiphospholipid antibodies (aPL) may induce acquired activated protein C resistance (acquired APCR). The role of acquired APCR in patients with systemic lupus erythematosus (SLE) is not well known. To evaluate the prevalenceof acquiredAPCR and its associationwith clinical manifestations we studied 103 consecutive SLE patients and 103 matched controls. APCR in the undiluted test and after dilution in factor V deficient plasma, factor V Leiden, protein C and S, lupus anticoagulant,and anti-cardiolipin,anti-ß2-glycoprotein I and anti-prothrombin antibodies were determined. Factor V Leiden was found in 4% in both patients and controls.The prevalenceof acquiredAPCR was 22% for the undiluted assay and 17% in the diluted test. In SLE patients,acquired APCR was associated with aPL (39 vs 13% in undiluted assay, P=0.007; and 33 vs 7% in the diluted test, P=0.001). Arterial thromboses were found in 24% of patients with acquired APCR and in 6% of patients without (P=0.04). However, no relationship was found with venous thrombosis. Acquired APCR was also associated with pregnancy losses: miscarriages in 70% of women with acquired APCR vs 32% in those without (P=0.03). Thus, in SLE patients acquired APCR seems to be associated with increased prevalence of arterial thrombosis and pregnancy losses.

Key Words: acquired activated protein C resistance factor V Leiden • antiphospholipid antibodies • systemic lupus erythematosus • thrombosis

Lupus, Vol. 11, No. 11, 730-735 (2002)
DOI: 10.1191/0961203302lu256oa


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
LupusHome page
J T Merrill
Antibodies and clinical features of the antiphospholipid syndrome as criteria for systemic lupus erythematosus
Lupus, November 1, 2004; 13(11): 869 - 876.
[Abstract] [PDF]


Home page
BloodHome page
J.-L. P. Brouwer, M. Bijl, N. J. G. M. Veeger, H. C. Kluin-Nelemans, and J. van der Meer
The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus
Blood, July 1, 2004; 104(1): 143 - 148.
[Abstract] [Full Text] [PDF]



Advertisement